DE69324362T2 - D-enzymzusammensetzungen und verfahren zu deren verwendung - Google Patents

D-enzymzusammensetzungen und verfahren zu deren verwendung

Info

Publication number: DE69324362T2
Authority: DE; Germany
Prior art keywords: enzyme; amino acid; synthetic; acid residues; substrate
Prior art date: 1992-06-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69324362T

Other languages

German (de)

English (en)

Other versions

DE69324362D1 (de

Inventor

Stephen Kent

Raymond Milton

Saskia Milton

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scripps Research Institute

Original Assignee

Scripps Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-05

Filing date

1993-06-07

Publication date

1999-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25403558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69324362(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-06-07 Application filed by Scripps Research Institute filed Critical Scripps Research Institute

1999-05-12 Publication of DE69324362D1 publication Critical patent/DE69324362D1/de

1999-08-26 Application granted granted Critical

1999-08-26 Publication of DE69324362T2 publication Critical patent/DE69324362T2/de

2013-06-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 80
239000000203 mixture Substances 0.000 title claims description 72
150000001875 compounds Chemical class 0.000 claims abstract description 52
125000000539 amino acid group Chemical group 0.000 claims abstract description 49
150000001413 amino acids Chemical class 0.000 claims abstract description 48
239000000126 substance Substances 0.000 claims abstract description 41
230000000694 effects Effects 0.000 claims abstract description 38
150000008574 D-amino acids Chemical class 0.000 claims abstract description 31
-1 selenol ester Chemical class 0.000 claims abstract description 11
229940088598 enzyme Drugs 0.000 claims description 210
102000004190 Enzymes Human genes 0.000 claims description 146
108090000790 Enzymes Proteins 0.000 claims description 146
108010043797 4-alpha-glucanotransferase Proteins 0.000 claims description 112
239000000758 substrate Substances 0.000 claims description 88
102000019197 Superoxide Dismutase Human genes 0.000 claims description 65
108010012715 Superoxide dismutase Proteins 0.000 claims description 65
238000006243 chemical reaction Methods 0.000 claims description 42
108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 claims description 37
230000015572 biosynthetic process Effects 0.000 claims description 34
108091005804 Peptidases Proteins 0.000 claims description 29
102000035195 Peptidases Human genes 0.000 claims description 29
239000004365 Protease Substances 0.000 claims description 29
230000001225 therapeutic effect Effects 0.000 claims description 27
239000007795 chemical reaction product Substances 0.000 claims description 24
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 19
238000002360 preparation method Methods 0.000 claims description 18
235000019419 proteases Nutrition 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 17
230000008569 process Effects 0.000 claims description 14
239000013078 crystal Substances 0.000 claims description 13
238000006460 hydrolysis reaction Methods 0.000 claims description 13
230000007062 hydrolysis Effects 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 11
229930014626 natural product Natural products 0.000 claims description 11
150000001408 amides Chemical class 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 9
238000012216 screening Methods 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
238000002441 X-ray diffraction Methods 0.000 claims description 7
238000006911 enzymatic reaction Methods 0.000 claims description 7
102000003846 Carbonic anhydrases Human genes 0.000 claims description 6
108090000209 Carbonic anhydrases Proteins 0.000 claims description 6
102000016938 Catalase Human genes 0.000 claims description 6
102000004157 Hydrolases Human genes 0.000 claims description 6
108090000604 Hydrolases Proteins 0.000 claims description 6
108010073038 Penicillin Amidase Proteins 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 6
108010053835 Catalase Proteins 0.000 claims description 5
108090000317 Chymotrypsin Proteins 0.000 claims description 5
150000001298 alcohols Chemical class 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 5
229960002376 chymotrypsin Drugs 0.000 claims description 5
208000037906 ischaemic injury Diseases 0.000 claims description 5
210000000056 organ Anatomy 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
102000004317 Lyases Human genes 0.000 claims description 4
108090000856 Lyases Proteins 0.000 claims description 4
108090000526 Papain Proteins 0.000 claims description 4
108090000284 Pepsin A Proteins 0.000 claims description 4
102000057297 Pepsin A Human genes 0.000 claims description 4
108090000631 Trypsin Proteins 0.000 claims description 4
102000004142 Trypsin Human genes 0.000 claims description 4
229940000406 drug candidate Drugs 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
229940055729 papain Drugs 0.000 claims description 4
235000019834 papain Nutrition 0.000 claims description 4
229940111202 pepsin Drugs 0.000 claims description 4
235000019833 protease Nutrition 0.000 claims description 4
230000000451 tissue damage Effects 0.000 claims description 4
231100000827 tissue damage Toxicity 0.000 claims description 4
239000012588 trypsin Substances 0.000 claims description 4
206010006811 Bursitis Diseases 0.000 claims description 3
108010051152 Carboxylesterase Proteins 0.000 claims description 3
102000013392 Carboxylesterase Human genes 0.000 claims description 3
102000000496 Carboxypeptidases A Human genes 0.000 claims description 3
108010080937 Carboxypeptidases A Proteins 0.000 claims description 3
108090000746 Chymosin Proteins 0.000 claims description 3
108060006006 Cytochrome-c peroxidase Proteins 0.000 claims description 3
102000019280 Pancreatic lipases Human genes 0.000 claims description 3
108050006759 Pancreatic lipases Proteins 0.000 claims description 3
108010055297 Sterol Esterase Proteins 0.000 claims description 3
208000000491 Tendinopathy Diseases 0.000 claims description 3
206010043255 Tendonitis Diseases 0.000 claims description 3
108090001109 Thermolysin Proteins 0.000 claims description 3
150000001735 carboxylic acids Chemical class 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
150000002825 nitriles Chemical class 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
238000012916 structural analysis Methods 0.000 claims description 3
201000004415 tendinitis Diseases 0.000 claims description 3
231100000331 toxic Toxicity 0.000 claims description 3
230000002588 toxic effect Effects 0.000 claims description 3
238000005809 transesterification reaction Methods 0.000 claims description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
208000001708 Dupuytren contracture Diseases 0.000 claims description 2
201000011275 Epicondylitis Diseases 0.000 claims description 2
208000007241 Experimental Diabetes Mellitus Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
208000004362 Penile Induration Diseases 0.000 claims description 2
208000020758 Peyronie disease Diseases 0.000 claims description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
208000004760 Tenosynovitis Diseases 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
229910001882 dioxygen Inorganic materials 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
201000008383 nephritis Diseases 0.000 claims description 2
230000009291 secondary effect Effects 0.000 claims description 2
238000005891 transamination reaction Methods 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
229960004373 acetylcholine Drugs 0.000 claims 2
229940116369 pancreatic lipase Drugs 0.000 claims 2
RWSXRVCMGQZWBV-RITPCOANSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-RITPCOANSA-N 0.000 claims 1
102000003992 Peroxidases Human genes 0.000 claims 1
238000011319 anticancer therapy Methods 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
229940125532 enzyme inhibitor Drugs 0.000 claims 1
239000002532 enzyme inhibitor Substances 0.000 claims 1
230000009401 metastasis Effects 0.000 claims 1
108040007629 peroxidase activity proteins Proteins 0.000 claims 1
102000005962 receptors Human genes 0.000 abstract description 8
108020003175 receptors Proteins 0.000 abstract description 8
150000007970 thio esters Chemical class 0.000 abstract description 4
108090000765 processed proteins & peptides Proteins 0.000 description 85
102000004196 processed proteins & peptides Human genes 0.000 description 51
102000004169 proteins and genes Human genes 0.000 description 45
108090000623 proteins and genes Proteins 0.000 description 45
238000003786 synthesis reaction Methods 0.000 description 44
229940024606 amino acid Drugs 0.000 description 43
229920001184 polypeptide Polymers 0.000 description 42
239000003112 inhibitor Substances 0.000 description 37
239000000047 product Substances 0.000 description 24
230000000875 corresponding effect Effects 0.000 description 21
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 18
230000002255 enzymatic effect Effects 0.000 description 17
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
239000000178 monomer Substances 0.000 description 13
150000008575 L-amino acids Chemical class 0.000 description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
239000004480 active ingredient Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 9
230000003993 interaction Effects 0.000 description 9
238000001727 in vivo Methods 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
238000004007 reversed phase HPLC Methods 0.000 description 8
235000002639 sodium chloride Nutrition 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 7
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
238000006555 catalytic reaction Methods 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000007478 fluorogenic assay Methods 0.000 description 7
235000011187 glycerol Nutrition 0.000 description 7
238000001038 ionspray mass spectrometry Methods 0.000 description 7
239000007790 solid phase Substances 0.000 description 7
MQPXOVRKKPPKFZ-QYKDHROSSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3r)-2-acetamido-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]hexyl]amino]hexanoyl]amino]-n-[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide Chemical compound CC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCC)CN[C@@H](CCCC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O MQPXOVRKKPPKFZ-QYKDHROSSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000007987 MES buffer Substances 0.000 description 6
108010022073 MVT 101 Proteins 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000000926 separation method Methods 0.000 description 6
238000010532 solid phase synthesis reaction Methods 0.000 description 6
241000894007 species Species 0.000 description 6
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 5
108090000371 Esterases Proteins 0.000 description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
238000001142 circular dichroism spectrum Methods 0.000 description 5
238000002288 cocrystallisation Methods 0.000 description 5
238000010511 deprotection reaction Methods 0.000 description 5
229960003699 evans blue Drugs 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000035404 Autolysis Diseases 0.000 description 3
101710167917 Carbonic anhydrase 2 Proteins 0.000 description 3
102100024633 Carbonic anhydrase 2 Human genes 0.000 description 3
206010057248 Cell death Diseases 0.000 description 3
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
102000004882 Lipase Human genes 0.000 description 3
108090001060 Lipase Proteins 0.000 description 3
239000004367 Lipase Substances 0.000 description 3
102000004316 Oxidoreductases Human genes 0.000 description 3
108090000854 Oxidoreductases Proteins 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000003078 antioxidant effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
235000019421 lipase Nutrition 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000000575 pesticide Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000010410 reperfusion Effects 0.000 description 3
230000002000 scavenging effect Effects 0.000 description 3
230000028043 self proteolysis Effects 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000000707 stereoselective effect Effects 0.000 description 3
229960002898 threonine Drugs 0.000 description 3
230000014616 translation Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000002424 x-ray crystallography Methods 0.000 description 3
NGEWQZIDQIYUNV-SCSAIBSYSA-N (R)-2-hydroxy-3-methylbutyric acid Chemical compound CC(C)[C@@H](O)C(O)=O NGEWQZIDQIYUNV-SCSAIBSYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
108010022752 Acetylcholinesterase Proteins 0.000 description 2
102100033639 Acetylcholinesterase Human genes 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 2
229930182845 D-isoleucine Natural products 0.000 description 2
AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 2
229930182822 D-threonine Natural products 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
MNQZXJOMYWMBOU-GSVOUGTGSA-N L-(-)-glyceraldehyde Chemical compound OC[C@H](O)C=O MNQZXJOMYWMBOU-GSVOUGTGSA-N 0.000 description 2
229930182844 L-isoleucine Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
102000002067 Protein Subunits Human genes 0.000 description 2
108010001267 Protein Subunits Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
229940022698 acetylcholinesterase Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
230000001851 biosynthetic effect Effects 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000002983 circular dichroism Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000003398 denaturant Substances 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000006870 function Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000002917 insecticide Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
238000004989 laser desorption mass spectroscopy Methods 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000006961 mixed inhibition Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
239000010453 quartz Substances 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
YQGDEPYYFWUPGO-GSVOUGTGSA-N (3r)-4-amino-3-hydroxybutanoic acid Chemical compound NC[C@H](O)CC(O)=O YQGDEPYYFWUPGO-GSVOUGTGSA-N 0.000 description 1
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
UEJJHQNACJXSKW-VIFPVBQESA-N (S)-thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H]1CCC(=O)NC1=O UEJJHQNACJXSKW-VIFPVBQESA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical class OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102100035687 Bile salt-activated lipase Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
241000589562 Brucella Species 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
108030002440 Catalase peroxidases Proteins 0.000 description 1
241000863012 Caulobacter Species 0.000 description 1
241001112696 Clostridia Species 0.000 description 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010012088 Fibrinogen Receptors Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100022339 Integrin alpha-L Human genes 0.000 description 1
108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
108091007476 Microbial Esterases Proteins 0.000 description 1
208000009233 Morning Sickness Diseases 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010034464 Periarthritis Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091007187 Reductases Proteins 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
241000242678 Schistosoma Species 0.000 description 1
102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
108050001286 Somatostatin Receptor Proteins 0.000 description 1
102000011096 Somatostatin receptor Human genes 0.000 description 1
235000009337 Spinacia oleracea Nutrition 0.000 description 1
244000300264 Spinacia oleracea Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
208000034850 Vomiting in pregnancy Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
239000011149 active material Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000004716 alpha keto acids Chemical class 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000005219 aminonitrile group Chemical group 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
238000005864 bromoacetylation reaction Methods 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000011116 calcium hydroxide Nutrition 0.000 description 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004182 chemical digestion Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000002109 crystal growth method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
239000000539 dimer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000007323 disproportionation reaction Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
150000002168 ethanoic acid esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000043543 human SOD3 Human genes 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000003317 industrial substance Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000014413 iron hydroxide Nutrition 0.000 description 1
NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000013332 literature search Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000037891 myocardial injury Diseases 0.000 description 1
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
239000003016 pheromone Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
235000011118 potassium hydroxide Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000002728 pyrethroid Substances 0.000 description 1
230000006340 racemization Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
108010004034 stable plasma protein solution Proteins 0.000 description 1
238000007250 stereoselective catalysis Methods 0.000 description 1
239000003203 stereoselective catalyst Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)

DE69324362T 1992-06-05 1993-06-07 D-enzymzusammensetzungen und verfahren zu deren verwendung Expired - Lifetime DE69324362T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89481792A	1992-06-05	1992-06-05
PCT/US1993/005441 WO1993025667A1 (fr)	1992-06-05	1993-06-07	Compositions d'enzymes d et methodes d'utilisation de ces compositions

Publications (2)

Publication Number	Publication Date
DE69324362D1 DE69324362D1 (de)	1999-05-12
DE69324362T2 true DE69324362T2 (de)	1999-08-26

Family

ID=25403558

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69324362T Expired - Lifetime DE69324362T2 (de)	1992-06-05	1993-06-07	D-enzymzusammensetzungen und verfahren zu deren verwendung
DE69334152T Revoked DE69334152T2 (de)	1992-06-05	1993-06-07	Verknüpftes D-Protein und Verfahren zur Identifizierung von Rezeptor Aktivität modulierenden Verbindungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69334152T Revoked DE69334152T2 (de)	1992-06-05	1993-06-07	Verknüpftes D-Protein und Verfahren zur Identifizierung von Rezeptor Aktivität modulierenden Verbindungen

Country Status (9)

Country	Link
US (5)	US6548279B1 (fr)
EP (2)	EP0647266B1 (fr)
JP (2)	JPH08501207A (fr)
AT (2)	ATE178650T1 (fr)
AU (2)	AU678768B2 (fr)
CA (1)	CA2137378C (fr)
DE (2)	DE69324362T2 (fr)
ES (1)	ES2290976T3 (fr)
WO (1)	WO1993025667A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6548279B1 (en) *	1992-06-05	2003-04-15	The Scripps Research Institute	D-enzyme compositions and methods of their use
US5780221A (en) *	1995-05-03	1998-07-14	Whitehead Institute For Biomedical Research	Identification of enantiomeric ligands
ES2293651T3 (es) *	1995-11-28	2008-03-16	Cephalon, Inc.	Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
US6277874B1 (en) *	1996-07-09	2001-08-21	University Of Cincinnati And Apologic, Incorporated	Methods for the treatment of apolipoprotein E related diseases
US6908757B1 (en)	1998-03-26	2005-06-21	The Procter & Gamble Company	Serine protease variants having amino acid deletions and substitutions
WO2000052155A2 (fr)	1999-03-05	2000-09-08	Maxygen, Inc.	Recombinaison d'acides nucleiques d'insertion modifies
US6946128B1 (en)	1999-07-22	2005-09-20	The Procter & Gamble Company	Protease conjugates having sterically protected epitope regions
KR20020021395A (ko)	1999-07-22	2002-03-20	데이비드 엠 모이어	입체적으로 보호된 ｃｌｉｐ 부위를 갖는 프로테아제콘쥬게이트
WO2001007575A2 (fr)	1999-07-22	2001-02-01	The Procter & Gamble Company	Variants de protease subtilisine possedant des suppressions et des substitutions d'acides amines dans certaines regions de sites antigeniques
BR0012660A (pt)	1999-07-22	2002-04-09	Procter & Gamble	Variante de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
CA2396320A1 (fr) *	2000-01-11	2001-07-19	Maxygen, Inc.	Systemes integres et procedes associes de production diversifiee et de criblage
US20030170846A1 (en) *	2000-04-24	2003-09-11	Weisgerber David John	Enzyme variants having one or more D-amino acid substitutions
US20050181464A1 (en) *	2002-04-04	2005-08-18	Affinium Pharmaceuticals, Inc.	Novel purified polypeptides from bacteria
US7588575B2 (en) *	2003-10-21	2009-09-15	Innovative Spinal Technologies	Extension for use with stabilization systems for internal structures
WO2010014830A2 (fr) *	2008-07-30	2010-02-04	Cosmix Therapeutics Llc	Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation
CA2817579A1 (fr)	2010-11-12	2012-04-14	Reflexion Pharmaceuticals, Inc.	Banques peptidiques gb 1 et composes associes, et leurs procedes de criblage
US8465413B2 (en)	2010-11-25	2013-06-18	Coloplast A/S	Method of treating Peyronie's disease
WO2013082531A2 (fr)	2011-12-02	2013-06-06	Reflexion Pharmaceuticals	Vaccins neutralisant la grippe a à large spectre et composés d-peptidiques et procédés de fabrication et d'utilisation de ceux-ci
CN104334196B (zh)	2012-02-16	2018-04-10	Atyr 医药公司	用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
US9238676B2 (en)	2012-05-17	2016-01-19	Ra Pharmaceuticals, Inc.	Peptide and peptidomimetic inhibitors
HK1218534A1 (zh)	2013-03-14	2017-02-24	多伦多大学管理委员会	支架化肽文库以及其制备和筛选方法
JP6296382B2 (ja) *	2015-05-11	2018-03-20	株式会社資生堂	結合型アミノ酸のキラル分析方法及びキラル分析システム

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE790240A (fr)	1971-10-19	1973-02-15	Sumitomo Chemical Co	Procede de preparation de l'acide mixte (+)-cis, (+)-trans- chrysanthemique
US3963573A (en)	1975-03-03	1976-06-15	The Procter & Gamble Company	Process for producing N-acyl-L-methionine
US4151198A (en)	1978-06-02	1979-04-24	American Cyanamid Company	Resolution of N-acyl-DL (+)-phenylalanines
FR2443452A1 (fr)	1978-12-08	1980-07-04	Roussel Uclaf	Nouveau procede de dedoublement de l'acide dl cis et dl trans chrysanthemique
US4262092A (en)	1979-05-08	1981-04-14	Ethyl Corporation	Process for producing N-acyl-D-phenylalanine ester
US4290893A (en)	1979-05-08	1981-09-22	Yeda Research & Development Co. Ltd.	Separation of amino acids by liquid chromatography using chiral eluants
US4423037A (en) *	1982-05-13	1983-12-27	The General Hospital Corporation	Inhibitors of peptide hormone action
US4454344A (en)	1982-08-23	1984-06-12	American Cyanamid Company	Method for the resolution of racemic 2-(p-difluoromethoxyphenyl)-3-methylbutyric acid
US5157019A (en) *	1986-03-18	1992-10-20	Monsanto Company	Serine protease inhibitors
US5066716A (en) *	1988-12-13	1991-11-19	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US5098836A (en) *	1989-08-14	1992-03-24	Phillips Petroleum Company	Deoxygenation in field preparation of polymers in aqueous solution
US5585353A (en) *	1990-02-02	1996-12-17	The Rockefeller University	Antibiotic peptides containing D-amino acids
DK0558671T3 (da) *	1990-11-21	1999-09-13	Iterex Pharma Lp	Syntese af ækvimolære multiple oligomerblandinger, især af oligopeptidblandinger
ES2185628T3 (es) *	1992-04-07	2003-05-01	Scripps Research Inst	Procedimiento para preparar proteinas modificadas.
US6548279B1 (en) *	1992-06-05	2003-04-15	The Scripps Research Institute	D-enzyme compositions and methods of their use
US5589356A (en) *	1993-06-21	1996-12-31	Vanderbilt University	Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
AU2531397A (en) *	1996-03-21	1997-10-10	President And Fellows Of Harvard College	Enantiomeric screening process, and compositions therefor

1993
- 1993-06-07 US US08/343,585 patent/US6548279B1/en not_active Expired - Lifetime
- 1993-06-07 AT AT93916447T patent/ATE178650T1/de not_active IP Right Cessation
- 1993-06-07 WO PCT/US1993/005441 patent/WO1993025667A1/fr active IP Right Grant
- 1993-06-07 AU AU45996/93A patent/AU678768B2/en not_active Expired
- 1993-06-07 CA CA002137378A patent/CA2137378C/fr not_active Expired - Lifetime
- 1993-06-07 EP EP93916447A patent/EP0647266B1/fr not_active Expired - Lifetime
- 1993-06-07 AT AT98108855T patent/ATE366744T1/de not_active IP Right Cessation
- 1993-06-07 DE DE69324362T patent/DE69324362T2/de not_active Expired - Lifetime
- 1993-06-07 ES ES98108855T patent/ES2290976T3/es not_active Expired - Lifetime
- 1993-06-07 EP EP98108855A patent/EP0882737B1/fr not_active Revoked
- 1993-06-07 JP JP6501660A patent/JPH08501207A/ja active Pending
- 1993-06-07 DE DE69334152T patent/DE69334152T2/de not_active Revoked
1996
- 1996-05-22 US US08/651,303 patent/US5910437A/en not_active Expired - Lifetime
- 1996-05-22 US US08/651,144 patent/US6040133A/en not_active Expired - Lifetime
1997
- 1997-09-12 AU AU37564/97A patent/AU721228B2/en not_active Expired
2002
- 2002-08-17 US US10/223,103 patent/US7135279B2/en not_active Expired - Fee Related
- 2002-08-27 US US10/229,553 patent/US7118856B2/en not_active Expired - Fee Related
2004
- 2004-01-23 JP JP2004016243A patent/JP4312615B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU678768B2 (en)	1997-06-12
EP0882737A1 (fr)	1998-12-09
US20040086988A1 (en)	2004-05-06
DE69324362D1 (de)	1999-05-12
AU3756497A (en)	1997-12-18
US20030113881A1 (en)	2003-06-19
DE69334152D1 (de)	2007-08-23
US7118856B2 (en)	2006-10-10
US6548279B1 (en)	2003-04-15
JPH08501207A (ja)	1996-02-13
ATE366744T1 (de)	2007-08-15
JP4312615B2 (ja)	2009-08-12
AU721228B2 (en)	2000-06-29
EP0647266A1 (fr)	1995-04-12
ES2290976T3 (es)	2008-02-16
CA2137378C (fr)	2008-08-05
CA2137378A1 (fr)	1993-12-23
US7135279B2 (en)	2006-11-14
US5910437A (en)	1999-06-08
ATE178650T1 (de)	1999-04-15
JP2004275180A (ja)	2004-10-07
DE69334152T2 (de)	2008-03-13
AU4599693A (en)	1994-01-04
US6040133A (en)	2000-03-21
EP0647266B1 (fr)	1999-04-07
WO1993025667A1 (fr)	1993-12-23
EP0882737B1 (fr)	2007-07-11

Publication	Publication Date	Title
DE69324362T2 (de)	1999-08-26	D-enzymzusammensetzungen und verfahren zu deren verwendung
DE68925972T2 (de)	1996-07-25	Heilungsverfahren unter verwendung katalytischer antikörper
WO1993025667A9 (fr)	1994-02-03	Compositions d'enzymes d et methodes d'utilisation de ces compositions
DE69131834T2 (de)	2000-05-31	Serinproteasevarianten mit peptidligase aktivität
DE69230043T2 (de)	2000-01-27	Materialien und methoden zur schädlingsbekämpfung
OA10066A (fr)	1996-10-14	Lipopeptides d'actinoplanes sp a activite pharmacologique procede pour leur production et leur utilisation
WO2001058446A1 (fr)	2001-08-16	Utilisation de solutes compatibles pour proteger des biopolymeres macromoleculaires contre une decomposition par des enzymes a pouvoir degradant
DE3889625T2 (de)	1994-09-29	Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung.
DE10006578A1 (de)	2001-08-23	Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
AU650254B2 (en)	1994-06-16	HIV protease inhibitors containing derived amino acid units
DE69736561T2 (de)	2007-08-23	Acyltransfer mit einem stabilisierten übergangskomplex unter verwendung eines katalysators mit einer katalytischen imidazolfunktion (z.b. histidin)
DE10220740A1 (de)	2003-11-27	Verfahren zur enzymatischen Herstellung enantiomerenangereicherter beta-Aminosäuren
JPS58189149A (ja)	1983-11-04	ヒトインシユリンの半合成方法
DE3739347A1 (de)	1989-06-01	Verfahren zur selektiven spaltung von fusionsproteinen
EP0321722B1 (fr)	1994-02-16	Procédé pour l'obtention de dipeptides
CN100340288C (zh)	2007-10-03	钙调磷酸酶的持久的活化抑制剂
DE2900926C2 (fr)	1991-01-17
DE4404168A1 (de)	1995-08-17	Hirudinderivate und Verfahren zu deren Herstellung
EP1312680A1 (fr)	2003-05-21	Procédé pour la synthèse de peptides de configuration all-D et de acides nucléiques peptidiques
DE19726012C1 (de)	1998-10-22	Verfahren zur Herstellung von Cyclopeptiden und Cyclodepsipeptiden durch enzymatische Synthese
Ghori et al.	1985	Functional relationship of ammonia with RNA, DNA, and protein in rat muscle
JPS62116597A (ja)	1987-05-28	人インシユリンの製造方法
EP0968279A1 (fr)	2000-01-05	Procede de purification et de cristallisation de proteasome

Legal Events

Date	Code	Title	Description
2000-05-04	8364	No opposition during term of opposition